Additional file 1 of A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape

Additional file 1: Table S1. The clinical data for each sample used in the training cohort. Table S2. The clinical data for each sample used in the validation cohort. Table S3. The clinical data for each sample used in the TCGA cohort. Table S4. Twenty-nine immune signatures were used to assess immune status. Table S5. Frequency of nonzero coefficients for 98 prognostic genes in 1000 LASSO analyses. Table S6. Gene sets enriched in the low-risk group. Table S7. Gene sets enriched in the high-risk group. Table S8. Functional enrichment analysis of 310 genes specifically amplified in the high-risk group. Table S9. Functional enrichment analysis of 1,218 genes specifically amplified in the low-risk group.